OPKO Health, Inc.
NASDAQ:OPKBiotechnology
+$0.01 today
- Market cap
- $1.25B
- Beta
- 1.49
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.28
Volume 3.06M
Average 2.59M
OPK Debt Repayment
Cash used to repay borrowings during the period.
OPKO Health, Inc.NASDAQ: OPK
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment declines year over year
Q1 FY2026 debt repayment of $390K (cash outflow) fell 90.5% year over year, ahead of the -132.8% change in trailing-twelve-month debt repayment. Sequentially, it fell 91.7% from the prior quarter.
Context
- Debt repayment amounted to 11.7% of revenue in FY2025, down 28.7 pp from a year earlier.
- Debt repayment increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -90.5% holds above the trailing-twelve-month pace of -132.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (70.76M) USD
- Year-over-year change
- -124.6%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (70.76M) | -124.6% |
| FY2024 | 2024-12-31 | 287.98M | +2710.7% |
| FY2023 | 2023-12-31 | (11.03M) | -146.5% |
| FY2022 | 2022-12-31 | 23.75M | +311.2% |
| FY2021 | 2021-12-31 | (11.24M) | — |
Debt Repayment vs competitors
How OPK compares with its peers on the latest reported figures
- OPK's LTM Mar 2026 debt repayment of $67.04M is the 2nd largest of the 11 companies compared; the peer median is $8.96M.
- Its year-over-year change of -132.8% is the 9th highest of 10, against a peer median of +100.0%.
- Debt repayment amounts to 11.5% of revenue for OPK, versus a peer median of 5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $396.04M | +7773.5% | — | 31.0% | |
| LTM Mar 2026 | $67.04M | -132.8% | — | 11.5% | |
| LTM Mar 2026 | $64.5M | +229.1% | — | 7.8% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $28.98M | — | — | 7.3% |
| FY2025 | $21.6M | +86.4% | -0.8% | 20.0% | |
| LTM Jun 2026 | $16M | +108.0% | +542.7% | 2.1% | |
| LTM Mar 2026 | $5.1M | -449.8% | — | 7.9% | |
| LTM Mar 2026 | $1.92M | +308.6% | — | 2.8% | |
| LTM Mar 2026 | $828K | -44.1% | -6.6% | 0.3% | |
| LTM Mar 2026 | $139K | +59.8% | -2.0% | 0.0% | |
| LTM Jun 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding OPK) | $8.96M | +100.0% | -1.4% | 5.0% | |
Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.14M) | (328.41M) | (188.86M) | (53.22M) | (225.68M) |
| Depreciation & Amortization | 78.72M | 108.66M | 105.3M | 98.18M | 91.63M |
| Deferred Income Tax | 10.16M | (74.41M) | 146K | 14.74M | (15M) |
| Stock-Based Compensation | 13.63M | 18.51M | 11.41M | 11.05M | 10.71M |
| Change in Working Capital | (20.48M) | 42.65M | 21.8M | 32.18M | (41.18M) |
| Accounts Receivables | 5.23M | 128.6M | 3.41M | (220K) | 30.21M |
| Inventory | 30.68M | 13.66M | 15.2M | 4.22M | (4.12M) |
| Accounts Payables | (10.85M) | (9.39M) | 2.83M | (20.66M) | (14.22M) |
| Other Working Capital | (45.55M) | (90.22M) | 363K | 48.84M | (53.06M) |
| Other Non-Cash Items | (13.55M) | 137.8M | 22.01M | (286.41M) | 976K |
| Operating Cash Flow | 38.34M | (95.19M) | (28.2M) | (183.49M) | (178.54M) |
| Capital Expenditures | (32.16M) | (24.58M) | (16.28M) | (25.01M) | (12.28M) |
| Acquisitions (Net) | (6M) | (1.76M) | (5M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.08M | 115.42M | 364K | 166.6M | 52.18M |
| Other Investing Activities | 66.03M | 1.95M | 2.71M | 210.62M | 190.39M |
| Investing Cash Flow | 35.95M | 91.04M | (18.2M) | 352.21M | 230.3M |
| Debt Repayment | (11.24M) | 23.75M | (11.03M) | 287.98M | (70.76M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | (256K) |
| Common Stock Repurchased | 0 | 0 | 0 | (90.22M) | (47.04M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 893K | (774K) | (272K) | (13.59M) | 0 |
| Financing Cash Flow | (10.35M) | 22.97M | (11.3M) | 184.17M | (118.06M) |
| Effect of Forex Changes | (1.44M) | (339K) | 388K | (3.16M) | 3.43M |
| Net Change in Cash | 62.5M | 18.48M | (57.31M) | 349.73M | (62.87M) |
| Free Cash Flow | 6.18M | (119.77M) | (44.47M) | (208.5M) | (190.82M) |
OPKO Health, Inc.
NASDAQ:OPK
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.